Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF Induction Chemotherapy for Locally Advanced Borderline-Resectable Esophageal Squamous Cell Carcinoma
NCT02976909Phase 2Completed
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: R0 Resection Rate at 36 months. Started Oct 2016; status: completed.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02976909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976909.